Physician profile
David W Nelson
NPI 1669494878
$255,883.37
in general payments reported to CMS, 2019-2025
19 companies · $5,006 in 2025
The $5,006 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $57K · 2021: $3,174 · 2022: $53K · 2023: $60K · 2024: $26K · 2025: $5,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90K · Travel and Lodging: $698 · Entertainment: $88.56 · Education: $27.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90,312.03 |
| Travel and Lodging | $697.85 |
| Entertainment | $88.56 |
| Education | $27.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $141,599.87 | 2021-2025 | Optilight |
| Optos, INC. | $107,519.92 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $1,868.60 | 2019-2025 | Precision7, Tryptyr, Dailies Total1 |
| Biotissue Holdings INC. | $1,403.88 | 2021-2025 | |
| Johnson & Johnson Vision Care, INC. | $759.80 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $577.66 | 2019-2021 | |
| Lkc Technologies, INC. | $544.54 | 2022-2023 | |
| Harrow Eye, LLC | $477.98 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $370.19 | 2022-2025 | Infuse, Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $214.04 | 2024-2025 | Xdemvy |
| Coopervision INC. | $110.12 | 2021-2025 | Myday Contact Lens, Misight Contact Lens |
| Horizon Therapeutics Plc | $108.38 | 2022 | |
| Rxsight INC | $68.59 | 2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Oyster Point Pharma, INC. | $68.50 | 2023-2025 | Tyrvaya |
| Maculogix, INC. | $62.79 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $61.26 | 2025 | Oxervate |
| Haag-Streit USA, INC. | $27.19 | 2023 | |
| Amgen INC. | $21.24 | 2024 | Tepezza |
| Abbvie INC. | $18.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.